Loxo's targeted therapy holds up to Roche challenge

Roche's targeted cancer therapy entrectinib drove strong response rates in patients whose tumors harbor a rare genetic mutation, trial results presented Sunday showed, helping to validate the Swiss pharma's decision from last year to buy the drug's developer, Ignyta.